ApoRopin, 2 mg, prolonged-release tablets
ApoRopin, 4 mg, prolonged-release tablets
ApoRopin, 8 mg, prolonged-release tablets
Ropinirole
The active substance of ApoRopin is ropinirole, which belongs to a group of medicines called dopamine agonists. Dopamine agonists work in the brain in a similar way to a naturally occurring substance called dopamine. ApoRopin prolonged-release tablets are used to treat Parkinson's disease. In patients with Parkinson's disease, there is a low level of dopamine in some parts of the brain. Ropinirole works in a similar way to dopamine in the brain, helping to alleviate the symptoms of Parkinson's disease.
Tell your doctor if any of the above applies to you.
Before taking ApoRopin, discuss with your doctor or pharmacist:
If you experience any of the following side effects after stopping or reducing the dose of ApoRopin, tell your doctor: depression, apathy, anxiety, lack of energy, sweating, or pain (called dopamine agonist withdrawal syndrome, or DAWS). If the symptoms persist for more than a few weeks, your doctor may decide to adjust the dose of ApoRopin. Tell your doctor if you, your family, or caregivers notice that you are developing unusual behaviors such as an excessive desire to gamble, increased libido, or uncontrolled spending. These behaviors are called impulse control disorders and can be treated. Tell your doctor if you, your family, or caregivers notice that you are experiencing episodes of excessive restlessness, excitement, or irritability. Your doctor may decide to adjust the dose or stop the treatment. Tell your doctor if any of the above applies to you. Your doctor may decide that ApoRopin is not suitable for you or may recommend additional monitoring while taking the medicine.
ApoRopin can be taken with or without food, according to your preference.
ApoRopin should not be used during pregnancy unless your doctor considers it essential. ApoRopin should not be used during breast-feeding as it may affect milk production. If you are pregnant, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before taking this medicine.
ApoRopin may cause drowsiness. Sudden sleepiness or sudden attacks of sleep without warning may occur. If you experience hallucinations, do not drive or operate machinery. If you experience any of the above, do not drive, operate machinery, or perform tasks that may put you or others at risk of serious injury or death. Do not perform such tasks until the symptoms have resolved. Talk to your doctor if this is a problem for you.
ApoRopin prolonged-release tablets contain lactose. If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicine. ApoRopin contains hydrogenated castor oil. This may cause stomach upset or diarrhea. The medicine contains less than 1 mmol (23 mg) of sodium per 2 mg, 4 mg, and 8 mg dose, which is essentially sodium-free.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
ApoRopin should not be given to children. ApoRopin is not usually prescribed for patients under 18 years old. ApoRopin can be used alone to treat the symptoms of Parkinson's disease. It can also be used in combination with another medicine called L-dopa (also known as levodopa). When starting ApoRopin, you may experience involuntary movements (dyskinesias). If you experience these symptoms, tell your doctor, who may adjust the doses of your medicines. ApoRopin prolonged-release tablets are designed to release the active substance over a period of more than 24 hours. If the medicine passes through your body too quickly (e.g., during diarrhea), the tablets may not dissolve completely and may not work as well as they should. You may see the tablets in your stool. If this happens, contact your doctor as soon as possible.
It may take some time to find the dose of ApoRopin that is right for you. The recommended starting dose of ApoRopin prolonged-release tablets is 2 mg once daily for the first week. Your doctor may increase the dose of ApoRopin prolonged-release tablets to 4 mg once daily from the second week of treatment. If you are elderly, your doctor may increase the dose more slowly. Your doctor will then adjust the dose until you reach the dose that is right for you. Some patients take up to 24 mg of ApoRopin prolonged-release tablets once daily. If you experience side effects that are difficult to tolerate at the start of treatment, tell your doctor. Your doctor may recommend switching to a lower dose of ropinirole in the form of immediate-release tablets, which you would take three times a day. Do not take more ApoRopin than your doctor has recommended. It may take several weeks for ApoRopin to start working.
Take ApoRopin once daily, at the same time each day. Swallow the prolonged-release tablet(s) whole with a glass of water. Do not break, chew, or crush the prolonged-release tablets. If you do, there is a risk of overdose due to the rapid release of the active substance.
Your doctor will determine the dose of ApoRopin prolonged-release tablets based on the dose of ropinirole immediate-release tablets you were taking. Take your last dose of ropinirole immediate-release tablets on the day before you start taking ApoRopin prolonged-release tablets. The next morning, take ApoRopin prolonged-release tablets and do not take any more ropinirole immediate-release tablets.
Contact your doctor or pharmacist immediately. If possible, show them the pack of ApoRopin. If you take more ApoRopin than you should, you may experience: nausea, vomiting, dizziness, drowsiness, mental fatigue, or fainting.
Do not take a double dose to make up for a forgotten dose. If you forget to take a dose of ApoRopin for one day or longer, consult your doctor for advice on restarting treatment.
Do not stop taking ApoRopin without consulting your doctor. ApoRopin should be taken for as long as your doctor recommends. Do not stop taking it unless your doctor tells you to. If you suddenly stop taking ApoRopin, your Parkinson's symptoms may quickly get much worse. Stopping treatment suddenly can also cause a serious syndrome called neuroleptic malignant syndrome, which can be life-threatening. Symptoms include: akinesia (loss of movement), muscle stiffness, fever, unstable blood pressure, rapid heartbeat, confusion, and reduced consciousness (e.g., coma). If your doctor decides to stop your treatment with ApoRopin, they will gradually reduce your dose. If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, ApoRopin can cause side effects, although not everybody gets them. Side effects are more likely to happen when you first start taking ApoRopin or when your dose is increased. They are usually mild and may improve after a few weeks of treatment. If you are concerned about side effects, talk to your doctor.
May affect more than 1 in 10 people taking ApoRopin:
May affect up to 1 in 10 people taking ApoRopin:
May affect up to 1 in 100 people taking ApoRopin:
In patients taking ApoRopin with levodopa, the following side effects may occur after some time:
If you experience any side effects, including any not listed in this leaflet, tell your doctor or pharmacist. Reporting of side effects If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Medicines Adverse Reaction Monitoring Department, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181 C, 02-222 Warsaw, tel.: 22 49-21-301, fax: 22 49-21-309, website: https://smz.ezdrowie.gov.pl. You can also report side effects to the marketing authorization holder.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the packaging after EXP. The expiry date refers to the last day of that month. Do not store above 30°C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
ApoRopin, 2 mg, prolonged-release tablets:
Pink, speckled, oval tablets, with "2x" engraved on one side.
ApoRopin, 4 mg, prolonged-release tablets:
Brown, speckled, oval tablets, with "4x" engraved on one side.
ApoRopin, 8 mg, prolonged-release tablets:
Dark pink, speckled, oval tablets, with "8x" engraved on one side.
Pack sizes:
ApoRopin prolonged-release tablets are available in blister packs of:
28, 30, 42, 56, 84, and 90 prolonged-release tablets.
Marketing authorization holder
ul. Sokratesa 13D lok. 27
01-909 Warsaw
Poland
Manufacturer
Actavis Ltd.
BLB 016 Bulebel Industrial Estate
Zejtun ZTN 3000
Malta
Date of last revision of the leaflet:15.12.2022
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.